Virpax Pharmaceuticals, Inc.

OTC: VRPX · Healthcare · Biotechnology

PublicHQ Berwyn, PA · ChesterCIK 0001708331Reports USD

#1 of 1,418 Healthcare companies by revenue

EA Score

——

FH —DQ —GM —SS 9

v0.1 · 5/100 weight · pillars only

↑ balance-sheet leverage, filing timeliness · ↓ Piotroski F, market scale

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$12.1M

Employees

as of 2026-08-29

Market cap

$124

as of 2026-08-29

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$12.1M-$12.1M2024

Operating income-$12.1M-$12.1M2024

Total assets$1.6M$1.6M2024

Liabilities$2.5M$2.5M2024

Equity-$913.8k-$913.8k2024

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Virpax Pharmaceuticals, Inc.’s financial profile?

Virpax Pharmaceuticals, Inc. earned -$12.1M in FY2024 net income.

Peers · Healthcare

Itoco Inc.——Regenicin, Inc.——CERo Therapeutics Holdings, Inc.——Binovi Technologies Corp.——Emerging World Pharma, Inc.——HEALTHeUNIVERSE, Inc.——

Neighbors

Chester →

AMETEK, Inc.$7.4B83B+West Pharmaceutical Services, Inc.$3.1B86A Bentley Systems, Incorporated$1.5B67B CubeSmart$1.1B62C Vishay Intertechnology, Inc.$3.1B71B Galera Therapeutics, Inc.——

Key facts

CEOJatinder Dhaliwal

SectorHealthcare

IndustryBiotechnology

HeadquartersBerwyn, PA

ExchangeOTC: VRPX

Employees2

IPO date2021-02-17

Latest filings

8-K2025-04-03 8-K2025-03-21 10-K2025-03-03 8-K2025-02-06 8-K2025-02-04 8-K2025-01-30 8-K2025-01-15 8-K2025-01-07

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.